Nature Cancer: Chinese Academy of Sciences Yu Huiyong team report: aldehyde ketone sase B through metabolic reprogramming to inhibit the occurrence of liver cancer

!---- metabolic reprogramming is the core marker of cancer, but its definition in the occurrence of hepatocellular carcinoma (HCC) is still vaguerecently, a team from the Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences found that the liver aldehyde glysase B (Aldob) inhibits HCC by directly binding and inhibiting the speed-limiting enzyme, glucose-6-phosphate dehydrogenase (G6PD), in the pathway of phosphoric acidthe stage reduction of Aldob and the increase of G6PD in human tumors were associated with adverse prognosis in HCC patientsglobal or liver-specific Aldob knockout promotes tumor development in mice by enhancing G6PD activity and gphosphoric acid pathway metabolism, while drug suppression or gene knockout of G6PD inhibits HCCconsistent, restoring aldob expression in mice with the Aldob gene knockout reduced tumor seisresearchers further demonstrate that Aldob enhances the inhibition of p53-mediated G6PD in the Aldob-G6PD-p53 complexthis stent effect is independent of Aldob enzyme activitytherefore, the study revealed a new metabolic reprogramming pattern in HCC due to aldob loss, a potential therapeutic strategy for HCC